Vyndamax, Vyndaqel(tafamidis)
Vyndamax, Vyndaqel (tafamidis) is a small molecule pharmaceutical. Tafamidis was first approved as Vyndaqel on 2011-11-16. It has been approved in Europe to treat amyloidosis. It is known to target transthyretin.
Download report
Favorite
FDA Novel Drug Approvals 2019
Top 200 Pharmaceuticals by Retail Sales
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nutritional and metabolic diseases | D009750 |
Trade Name
FDA
EMA
Vyndamax, Vyndaqel
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| vyndamax vyndaqel | New Drug Application | 2020-04-22 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
TAFAMIDIS, VYNDAMAX, FOLDRX PHARMS | |||
| 2026-05-03 | ODE-237 | ||
| 2024-05-03 | NCE | ||
TAFAMIDIS MEGLUMINE, VYNDAQEL, FOLDRX PHARMS | |||
| 2026-05-03 | ODE-237 | ||
| 2024-05-03 | NCE | ||
HCPCS
No data
Clinical
Clinical Trials
33 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cardiomyopathies | D009202 | EFO_0000318 | I42 | — | 1 | — | — | — | 1 |
| Nervous system lead poisoning adult | D020265 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 14 | — | — | — | — | 14 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Takotsubo cardiomyopathy | D054549 | EFO_1002000 | I51.81 | — | — | — | — | 1 | 1 |
| Polyneuropathies | D011115 | EFO_0009562 | A69.22 | — | — | — | — | 1 | 1 |
| Hereditary amyloidosis transthyretin-related | C567782 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | TAFAMIDIS |
| INN | tafamidis |
| Description | Tafamidis is a member of the class of 1,3-benzoxazoles that is 1,3-benzoxazole-6-carboxylic acid in which the hydrogen at position 2 is replaced by a 3,5-dichlorophenyl group. Used (as its meglumine salt) for the amelioration of transthyretin-related hereditary amyloidosis. It has a role as a central nervous system drug. It is a member of 1,3-benzoxazoles, a monocarboxylic acid and a dichlorobenzene. It is a conjugate acid of a tafamidis(1-). |
| Classification | Small molecule |
| Drug class | antimyloidotics |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | O=C(O)c1ccc2nc(-c3cc(Cl)cc(Cl)c3)oc2c1 |
Identifiers
| PDB | 6E72 |
| CAS-ID | 594839-88-0 |
| RxCUI | 1545063 |
| ChEMBL ID | CHEMBL2103837 |
| ChEBI ID | 78538 |
| PubChem CID | 11001318 |
| DrugBank | DB11644 |
| UNII ID | 8FG9H9D31J (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
Variants
Clinical Variant
No data
Financial
Vyndaqel - Pfizer
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,397 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
29,624 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more